Dr Chen is an early career researcher in Clinical trials and stroke.  She has vast experience in large scale stroke trials and has been pivotal to the success of multiple world-class large international clinical trials, including as Global Project Lead of The third, INTEnsive care bundle with blood pressure Reduction in Acute Cerebral haemorrhage Trial (INTERACT3) with 7000+ stroke patients enrolled from 130+ centres from 10 countries, Global Project Lead of the completed Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED), and Project manager of The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2) and The Sleep Apnea Cardiovascular Endpoints (SAVE) study.

As the Lead on stroke and digital health themes in Global Brain Health Program at the George Institute for Global Health, Dr Chen leads and collaborates with international experts on developing a multi-factorial, multi-arm, multi-stage, global randomised adaptive platform trial for stroke, and leads multiple digital health projects including OPTICS, a project to develop a decision supporting system which will be based on predictive models developed using deep learning techniques on the large amount of clinical data and imaging data in Intracerebral haemorrhage to assist clinician’s decision-making; FULMA, a project to develop an upper limb function assessment system with artificial intelligence and multimedia technology to help rehabilitation for chronic stroke patients with upper limb impairment; and CONNECT, a clinical trial to evaluate a medical device called Nuroflux which is a wearable device that can continuously monitor brain activities and blood flow, to demonstrate its efficacy in acute ischaemic stroke patients to detect neurological deteriorations.